Nrf2 as a Therapeutic Target in the Resistance to Targeted Therapies in Melanoma
The use of specific inhibitors towards mutant BRAF (BRAFi) and MEK (MEKi) in BRAF-mutated patients has significantly improved progression-free and overall survival of metastatic melanoma patients. Nevertheless, half of the patients still develop resistance within the first year of therapy. Therefore...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
MDPI AG
2023-06-01
|
| Seri Bilgileri: | Antioxidants |
| Konular: | |
| Online Erişim: | https://www.mdpi.com/2076-3921/12/6/1313 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|